These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 6446394

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Five-day therapy with cephradine capsules, 500 mg BID, for the treatment of acute, uncomplicated urinary tract infections.
    Brosof AB.
    Clin Ther; 1980; 3(4):285-91. PubMed ID: 7023676
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [1st personal experiences with carbenicillin therapy of urinary tract infections due to Pseudomonas aeruginosa].
    De Rosa F.
    G Mal Infett Parassit; 1971 Nov; 23(11):1068-70. PubMed ID: 5004854
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
    Wells WG, Woods GL, Jiang Q, Gesser RM.
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
    [Abstract] [Full Text] [Related]

  • 31. [Clinical trials of carbenicillin therapy in infections due to Pseudomonas aeruginosa].
    Malfatti S, Pardini C, Silvi G.
    G Mal Infett Parassit; 1971 Nov; 23(11):1063-8. PubMed ID: 5004853
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Newer carbapenems for urinary tract infections.
    Matsumoto T, Muratani T.
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S35-8. PubMed ID: 15364304
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H, Azap OK, Ergönül O, Timurkaynak F, Urinary Tract Infection Study Group.
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.